Financial_NN
summary_NN
Growth_NN
2005_CD
2004_CD
m_NN
m_NN
CER_NN
%_NN
%_NN
Turnover_NN
21,660_CD
19,986_CD
7_CD
8_CD
Operating_GER
profit_NN
6,874_CD
5,756_CD
16_CD
19_CD
profit_NN
before_IN
taxation_NOMZ
6,732_CD
5,779_CD
13_CD
16_CD
profit_NN
after_IN
taxation_NOMZ
for_PIN
the_DT
year_NN
4,816_CD
4,022_CD
17_CD
20_CD
profit_NN
attributable_JJ
to_PIN
minority_NOMZ
interests_NN
127_CD
114_CD
profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,689_CD
3,908_CD
Earnings_GER
per_PIN
share_NN
82.6_CD
p_VPRT
68.1_CD
p_JJ
18_CD
21_CD
Diluted_VBN
earnings_GER
per_PIN
share_NN
82.0_CD
p_NN
68.0_CD
p_NN
Dividends_NN
per_PIN
share_NN
44p_CD
42p_CD
Net_JJ
cash_NN
inow_NN
from_PIN
operating_VBG
activities_NOMZ
5,958_CD
4,944_CD
Net_JJ
assets_NN
7,570_CD
5,937_CD
History_NN
and_PHC
development_NOMZ
of_PIN
the_DT
company_NN
GlaxoSmithKline_NN
plc_NN
is_VPRT [BEMA]
a_DT
public_JJ
limited_JJ
company_NN
incorporated_VBN [WZPAST]
on_PIN
6th_JJ
December_NN
1999_CD
under_IN
English_JJ
law_NN
._.
Its_PIT
shares_NN
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
and_CC
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
On_PIN
27th_JJ
December_NN
2000_CD
the_DT
company_NN
acquired_VBD
Glaxo_NN
Wellcome_NN
plc_NN
and_PHC
SmithKline_NN
Beecham_NN
plc_NN
,_,
both_DT
English_JJ
public_JJ
limited_JJ
companies_NN
,_,
by_PIN
way_NN
of_PIN
a_DT
scheme_NN
of_PIN
arrangement_NOMZ
for_PIN
the_DT
merger_NN
of_PIN
the_DT
two_CD
companies_NN
._.
Both_DT
Glaxo_NN
Wellcome_NN
and_PHC
SmithKline_NN
Beecham_NN
were_VBD [BEMA]
major_JJ
global_JJ
healthcare_NN
businesses_NOMZ
._.
GSK_NN
plc_NN
and_CC
its_PIT
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
constitute_VPRT
a_DT
major_JJ
global_JJ
healthcare_NN
group_NN
engaged_VBD
in_PIN
the_DT
creation_NOMZ
,_,
discovery_NN
,_,
development_NOMZ
,_,
manufacture_NN
and_PHC
marketing_GER
of_PIN
pharmaceutical_JJ
and_CC
consumer_NN
health-related_JJ
products_NN
._.
GSK_NN
has_VPRT
its_PIT
corporate_JJ
head_NN
ofce_NN
in_PIN
London_NN
._.
It_PIT
also_RB
has_VPRT
operational_JJ
headquarters_NN
in_PIN
Philadelphia_NN
and_PHC
Research_NN
Triangle_NN
Park_NN
,_,
USA_NN
,_,
and_ANDC
operations_NOMZ
in_PIN
some_QUAN
119_CD
countries_NN
,_,
with_PIN
products_NN
sold_VBN [WZPAST]
in_PIN
over_IN
130_CD
countries_NN
._.
The_DT
principal_JJ
research_NN
and_PHC
development_NOMZ
R&D_NN
facilities_NOMZ
are_VPRT [BEMA]
in_PIN
the_DT
UK_NN
,_,
the_DT
USA_NN
,_,
Japan_NN
,_,
Italy_NN
,_,
Spain_NN
and_PHC
Belgium_NN
._.
Products_NN
are_VPRT [SPAU] [PASS]
currently_RB
manufactured_VBN
in_PIN
some_QUAN
37_CD
countries_NN
._.
The_DT
major_JJ
markets_NN
for_PIN
the_DT
Groups_NN
products_NN
are_VPRT [BEMA]
the_DT
USA_NN
,_,
France_NN
,_,
Japan_NN
,_,
the_DT
UK_NN
,_,
Italy_NN
,_,
Germany_NN
and_PHC
Spain_NN
._.
Business_NOMZ
segments_NOMZ
GSK_NN
operates_VPRT
principally_RB
in_PIN
two_CD
industry_NN
segments_NOMZ
:_:
Pharmaceuticals_NN
prescription_NOMZ
pharmaceuticals_NN
and_PHC
vaccines_NN
Consumer_NN
Healthcare_NN
over-the-counter_JJ
medicines_NN
,_,
oral_JJ
care_NN
and_CC
nutritional_JJ
healthcare_NN
._.
The_DT
Group_NN
,_,
as_IN
a_DT
multinational_JJ
business_NOMZ
,_,
operates_VPRT
in_PIN
many_QUAN
countries_NN
and_CC
earns_VPRT
revenues_NN
and_CC
incurs_VPRT
costs_NN
in_PIN
many_QUAN
currencies_NN
._.
The_DT
results_NN
of_PIN
the_DT
Group_NN
,_,
as_IN
reported_VBN [PUBV]
in_PIN
sterling_GER
,_,
are_VPRT [SPAU] [BYPA]
therefore_CONJ
affected_VBN
by_PIN
movements_NOMZ
in_PIN
exchange_NN
rates_NN
between_PIN
sterling_GER
and_CC
overseas_PLACE
currencies_NN
._.
Average_JJ
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
during_PIN
the_DT
period_NN
are_VPRT [PASS]
used_VBN
to_TO
translate_VB
the_DT
results_NN
and_PHC
cash_NN
ows_NN
of_PIN
overseas_PLACE
subsidiary_NN
and_CC
associated_VBN
undertakings_GER
and_CC
joint_JJ
ventures_NN
into_PIN
sterling_GER
._.
Period_NN
end_NN
rates_NN
are_VPRT [PASS]
used_VBN
to_TO
translate_VB
the_DT
net_JJ
assets_NN
of_PIN
those_DEMO
undertakings_GER
._.
The_DT
currencies_NN
which_WDT
most_EMPH
inuence_JJ
these_DEMO
translations_NOMZ
are_VPRT [BEMA]
the_DT
US_FPP1
dollar_NN
,_,
the_DT
Euro_NN
and_CC
the_DT
Japanese_JJ
Yen_NN
._.
In_PIN
order_NN
to_TO
illustrate_VB
underlying_VBG
performance_NN
,_,
it_PIT
is_VPRT [BEMA]
the_DT
Groups_NN
practice_NN
to_TO
discuss_VB
its_PIT
results_NN
in_PIN
terms_NN
of_PIN
constant_JJ
exchange_NN
rate_NN
CER_NN
growth_NN
._.
This_DEMP
represents_VPRT
growth_NN
calculated_VBN [PRIV]
as_IN
if_COND
the_DT
exchange_NN
rates_NN
used_VBN
to_TO
determine_VB [SUAV] [PRIV]
the_DT
results_NN
of_PIN
overseas_PLACE
companies_NN
in_PIN
sterling_GER
had_VBD [PEAS]
remained_VBN
unchanged_JJ
from_PIN
those_DEMP
used_VBN
in_PIN
the_DT
previous_JJ
year_NN
._.
CER_CD
%_NN
represents_VPRT
growth_NN
at_PIN
constant_JJ
exchange_NN
rates_NN
._.
%_NN
represents_VPRT
growth_NN
at_PIN
actual_JJ
exchange_NN
rates_NN
._.
Cautionary_JJ
statement_NOMZ
regarding_VBG [WZPRES]
forward-looking_JJ
statements_NOMZ
The_DT
Group_NN
's_POS
reports_NN
led_VBD
with_PIN
or_CC
furnished_VBN
to_PIN
the_DT
US_FPP1
Securities_NOMZ
and_PHC
Exchange_NN
Commission_NN
SEC_NN
,_,
including_VBG [PRESP]
this_DEMO
document_NOMZ
and_CC
written_VBN [PUBV] [THATD]
information_NOMZ
released_VBN
,_,
or_CC
oral_JJ
statements_NOMZ
made_VBN
,_,
to_PIN
the_DT
public_NN
in_PIN
the_DT
future_NN
by_PIN
or_CC
on_PIN
behalf_NN
of_PIN
the_DT
Group_NN
,_,
may_POMD
contain_VB
forward-looking_JJ
statements_NOMZ
._.
Forward-looking_VBG
statements_NOMZ
give_VPRT
the_DT
Group_NN
's_POS
current_JJ
expectations_NOMZ
or_CC
forecasts_NN
of_PIN
future_JJ
events_NN
._.
An_DT
investor_NN
can_POMD
identify_VB
these_DEMO
statements_NOMZ
by_PIN
the_DT
fact_NN
that_TOBJ
they_TPP3
do_VPRT
not_XX0
relate_VB
strictly_RB
to_PIN
historical_JJ
or_CC
current_JJ
facts_NN
._.
They_TPP3
use_VPRT
words_NN
such_JJ
as_IN
anticipate_VPRT [PRIV]
,_,
estimate_VPRT [PRIV]
,_,
expect_VPRT [PRIV]
,_,
intend_VPRT [SUAV]
,_,
will_PRMD
,_,
project_NN
,_,
plan_NN
,_,
believe_VB [PRIV]
and_CC
other_JJ
words_NN
and_PHC
terms_NN
of_PIN
similar_JJ
meaning_GER
in_PIN
connection_NOMZ
with_PIN
any_QUAN
discussion_NN
of_PIN
future_JJ
operating_GER
or_CC
financial_JJ
performance_NN
._.
In_CONJ
particular_NULL
,_,
these_DEMP
include_VPRT
statements_NOMZ
relating_VBG [WZPRES]
to_PIN
future_JJ
actions_NOMZ
,_,
prospective_JJ
products_NN
or_CC
product_NN
approvals_NN
,_,
future_JJ
performance_NN
or_CC
results_NN
of_PIN
current_JJ
and_PHC
anticipated_JJ
products_NN
,_,
sales_NN
efforts_NN
,_,
expenses_NN
,_,
the_DT
outcome_NN
of_PIN
contingencies_NN
such_JJ
as_IN
legal_JJ
proceedings_GER
,_,
and_ANDC
financial_JJ
results_NN
._.
The_DT
Group_NN
undertakes_VPRT
no_SYNE
obligation_NOMZ
to_TO
update_VB
any_QUAN
forward-looking_JJ
statements_NOMZ
,_,
whether_IN
as_CONJ
a_NULL
result_NULL
of_PIN
new_JJ
information_NOMZ
,_,
future_JJ
events_NN
or_CC
otherwise_CONJ
._.
Forward-looking_VBG
statements_NOMZ
involve_VPRT
inherent_JJ
risks_NN
and_PHC
uncertainties_NN
._.
The_DT
Group_NN
cautions_VPRT
investors_NN
that_TOBJ
a_DT
number_NN
of_PIN
important_JJ
factors_NN
,_,
including_VBG [PRESP]
those_DEMO
in_PIN
this_DEMO
document_NOMZ
,_,
could_POMD
cause_VB
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMP
contained_VBN
in_PIN
any_QUAN
forward-looking_JJ
statement_NOMZ
._.
Such_JJ
factors_NN
include_VPRT
,_,
but_CC
are_VPRT [PASS]
not_XX0
limited_VBN
to_TO
,_,
those_DEMP
discussed_VBN
under_IN
Risk_NN
factors_NN
on_PIN
pages_NN
71_CD
to_PIN
74_CD
of_PIN
this_DEMO
Annual_JJ
Report_NN
._.
GSK_NN
Annual_JJ
Report_NN
2005_CD
04_CD
REPORT_NN
OF_PIN
THE_DT
DIRECTORS_NN
